Icure Pharmaceutical Incorporation (175250) - Total Liabilities

Latest as of June 2025: ₩80.55 Billion KRW ≈ $54.59 Million USD

Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has total liabilities worth ₩80.55 Billion KRW (≈ $54.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Icure Pharmaceutical Incorporation long-term investment allocation to see how much of total assets are deployed in long-term investments.

Icure Pharmaceutical Incorporation - Total Liabilities Trend (2015–2024)

This chart illustrates how Icure Pharmaceutical Incorporation's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 175250 total assets.

Icure Pharmaceutical Incorporation Competitors by Total Liabilities

The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their total liabilities.

Company	Country	Total Liabilities
Shandong Chenming Paper Holdings Ltd Class B SHE:200488	China	HK$48.86 Billion
Aptech Limited NSE:APTECHT	India	Rs1.79 Billion
American Creek Resources Ltd V:AMK	Canada	CA$30.45K
EM-Tech.CO. LTD KQ:091120	Korea	₩135.58 Billion
Bangkok Ranch PCL BK:BR	Thailand	฿4.72 Billion
ALT Telecom Public Company Limited BK:ALT	Thailand	฿2.54 Billion
CanAlaska Uranium Ltd V:CVV	Canada	CA$7.08 Million
Aurea SA PA:AURE	France	€119.46 Million

Liability Composition Analysis (2015–2024)

This chart breaks down Icure Pharmaceutical Incorporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Icure Pharmaceutical Incorporation's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.71	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.61	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.62	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Icure Pharmaceutical Incorporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Icure Pharmaceutical Incorporation (2015–2024)

The table below shows the annual total liabilities of Icure Pharmaceutical Incorporation from 2015 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩72.62 Billion ≈ $49.22 Million	-31.84%
2023-12-31	₩106.54 Billion ≈ $72.20 Million	-20.76%
2022-12-31	₩134.45 Billion ≈ $91.11 Million	+12.33%
2021-12-31	₩119.69 Billion ≈ $81.11 Million	+44.22%
2020-12-31	₩82.99 Billion ≈ $56.24 Million	-29.82%
2019-12-31	₩118.27 Billion ≈ $80.15 Million	+225.73%
2018-12-31	₩36.31 Billion ≈ $24.61 Million	-0.32%
2017-12-31	₩36.43 Billion ≈ $24.69 Million	+149.76%
2016-12-31	₩14.58 Billion ≈ $9.88 Million	-27.76%
2015-12-31	₩20.19 Billion ≈ $13.68 Million	--

About Icure Pharmaceutical Incorporation

KQ:175250 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$54.96 Million

₩81.09 Billion KRW

Market Cap Rank

#21641 Global

#1289 in Korea

Share Price

₩2170.00

Change (1 day)

+0.00%

52-Week Range

₩2170.00 - ₩2170.00

All Time High

₩23730.97